Wall Street analyst estimates for Illumina, Inc. (ILMN): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains.
Consensus price target
$252.73 (+7 % vs price $235.99)
between $155.00 and $305.00 · 13 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $4.6B | $4.6B – $4.6B | $5.35 | 12 |
| 2027E | $4.9B | $4.8B – $5.0B | $6.10 | 12 |
| 2028E | $5.3B | $5.0B – $5.6B | $6.98 | 7 |
Figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 1 |
| Buy | 26 |
| Hold | 17 |
| Sell | 6 |
| Strong Sell | 0 |
| Total analysts | 50 |
| Avg rating (−2 sell to +2 buy) | 0.44 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-04 | $1.50 | ||
| 2026-10-29 | $1.62 | $1.36 | +19.1% |
| 2026-07-30 | $1.31 | $1.23 | +6.5% |
| 2026-04-30 | $1.15 | $1.05 | +9.5% |
| 2026-02-05 | $1.35 | $1.24 | +8.9% |
| 2025-10-30 | $1.34 | $1.17 | +14.5% |
| 2025-07-31 | $1.19 | $1.02 | +16.7% |
| 2025-05-08 | $0.97 | $0.94 | +3.2% |
Valuation Ratios
| P/E Ratio | 40.55 |
| Price / Book | 11.33 |
| EV / EBITDA | 26.39 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $10.0M | $28.0M | $50.6M | $73.5M | $184.6M | $366.8M | $573.2M | $666.3M | $902.7M | $1.06B | $1.15B | $1.42B | $1.86B | $2.22B | $2.40B | $2.75B | $3.33B | $3.54B | $3.24B | $4.53B | $4.58B | $4.50B | $4.37B | $4.34B |
| Cost of Revenue | $557,000 | $3.5M | $10.0M | $13.3M | $23.2M | $59.3M | $132.4M | $205.6M | $205.8M | $301.2M | $346.4M | $375.0M | $509.3M | $563.6M | $671.0M | $732.0M | $926.0M | $1.03B | $1.08B | $1.04B | $1.37B | $1.61B | $1.76B | $1.51B | $1.45B |
| Gross Profit | $1.9M | $6.5M | $18.0M | $37.3M | $50.3M | $125.2M | $234.4M | $367.6M | $460.6M | $601.5M | $709.1M | $773.5M | $911.9M | $1.30B | $1.55B | $1.67B | $1.83B | $2.30B | $2.47B | $2.20B | $3.15B | $2.97B | $2.74B | $2.86B | $2.89B |
| Research & Development | $20.7M | $26.8M | $22.5M | $21.1M | $27.7M | $33.4M | $73.9M | $100.0M | $140.6M | $177.9M | $196.9M | $231.0M | $276.7M | $388.1M | $401.5M | $504.4M | $546.0M | $623.0M | $647.0M | $682.0M | $1.19B | $1.32B | $1.35B | $1.17B | $951.0M |
| Selling, General & Admin | $5.7M | $9.1M | $18.9M | $25.1M | $28.0M | $54.1M | $101.3M | $148.0M | $176.3M | $220.5M | $261.8M | $286.0M | $381.0M | $466.3M | $516.0M | $584.0M | $674.0M | $794.0M | $835.0M | $941.0M | $2.09B | $1.30B | $1.61B | $1.09B | $1.08B |
| Operating Expenses | $32.2M | $48.4M | $44.6M | $42.8M | $71.8M | $87.4M | $535.6M | $287.1M | $335.0M | $389.9M | $509.6M | $572.8M | $777.8M | $783.0M | $936.0M | $1.08B | $1.22B | $1.42B | $1.48B | $1.62B | $3.28B | $7.15B | $3.81B | $3.69B | $2.03B |
| Operating Income | -$30.3M | -$41.9M | -$26.6M | -$5.5M | -$21.4M | $37.8M | -$301.2M | $80.5M | $125.6M | $211.7M | $199.5M | $200.8M | $134.1M | $514.7M | $613.0M | $587.0M | $606.0M | $883.0M | $985.0M | $580.0M | -$123.0M | -$4.18B | -$1.07B | -$833.0M | $864.0M |
| EBITDA | -$22.6M | -$32.4M | -$19.2M | -$515,000 | -$1.6M | $43.5M | $18.0M | $122.6M | $169.0M | $252.0M | $237.0M | $325.7M | $296.9M | $603.1M | $753.0M | $735.0M | $1.24B | $1.13B | $1.36B | $1.09B | $1.20B | -$3.92B | -$608.0M | -$725.0M | $1.46B |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $22.2M | $23.7M | $24.6M | $34.8M | $37.8M | $39.7M | $41.7M | $43.0M | $33.0M | $37.0M | $57.0M | $52.0M | $49.0M | $61.0M | $26.0M | $77.0M | $100.0M | $101.0M |
| Pre-tax Income | 0 | 0 | 0 | 0 | 0 | $42.6M | -$288.8M | $72.7M | $114.1M | $185.4M | $133.0M | $222.6M | $159.3M | $448.8M | $583.0M | $561.0M | $1.04B | $894.0M | $1.12B | $856.0M | $884.0M | -$4.34B | -$1.12B | -$1.18B | $1.09B |
| Income Tax | 0 | 0 | 0 | 0 | 0 | $2.7M | -$10.4M | $33.3M | $41.8M | $60.5M | $46.4M | $71.4M | $34.0M | $95.4M | $125.0M | $133.0M | $365.0M | $112.0M | $128.0M | $200.0M | $122.0M | $68.0M | $44.0M | $44.0M | $236.0M |
| Net Income | -$24.8M | -$40.3M | -$27.1M | -$6.2M | -$20.9M | $40.0M | -$278.4M | $50.5M | $72.3M | $124.9M | $86.6M | $151.3M | $125.3M | $353.4M | $461.6M | $462.6M | $726.0M | $826.0M | $1.00B | $656.0M | $762.0M | -$4.40B | -$1.16B | -$1.22B | $850.0M |
| EPS | $-0.42 | $-0.65 | $-0.42 | $-0.09 | $-0.26 | $0.45 | $-2.57 | $0.43 | $0.59 | $1.01 | $0.70 | $1.23 | $1.00 | $2.61 | $3.18 | $3.15 | $4.97 | $5.62 | $6.82 | $4.46 | $5.08 | $-28.05 | $-7.35 | $-7.69 | $5.48 |
| EPS (Diluted) | $-0.42 | $-0.65 | $-0.42 | $-0.09 | $-0.26 | $0.41 | $-2.57 | $0.38 | $0.53 | $0.87 | $0.62 | $1.13 | $0.90 | $2.37 | $3.10 | $3.13 | $4.91 | $5.54 | $6.72 | $4.43 | $5.05 | $-28.05 | $-7.35 | $-7.69 | $5.45 |
| Shares Outstanding (Diluted) | 59.5 M | 61.8 M | 63.9 M | 71.7 M | 80.3 M | 97.5 M | 108.3 M | 133.6 M | 137.1 M | 143.4 M | 138.9 M | 133.7 M | 139.9 M | 149.0 M | 149.0 M | 148.0 M | 148.0 M | 149.0 M | 149.0 M | 148.0 M | 151.0 M | 157.0 M | 158.0 M | 159.0 M | 156.0 M |
Price
| Price | $235.99 (closing price, October 30, 2026) |
| Market Cap | $35.6B |
| Exchange | NASDAQ |
| Country | US |
Related companies: NTRA · GH · BLLN · TXG · WGS · NEO
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of ILMN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks